KBKylie Baldwin

Kylie Baldwin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Research Subjects


Kylie Baldwin has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    CD20 antigen loss post‐venetoclax/anti‐ CD20 therapy in chronic lymphocytic leukaemia: Frequency, characteristics and potential therapeutic implications

    by Tamasine Stewart, Sean McKeague, Divya Somasekharannair, Lei‐Shong Lau, Ashley Whitechurch, Joshua Casan, Neil Came, Kylie Baldwin, Vuong Nguyen, Ing Soo Tiong, et al.

    Summary: Venetoclax plus anti‐CD20 monoclonal antibody (mAb) regimens have revolutionised treatment for chronic lymphocytic leukaemia (CLL); however, CD20 antigen loss is a potential consequence. Given emerging roles for re‐treatment with venetoclax plus anti‐CD20 mAb and CD20‐targeting bispecific antibodies in CLL, we retrospectively assessed the prevalence of CD20‐negative CLL in patients treated with fixed‐duration venetoclax/obinutuzumab (Ven‐O) or venetoclax/rituximab (Ven‐R). CD20 expression was assessed by flow cytometry at baseline, end of treatment (EOT) and disease progression, with negativity defined if the log difference in median fluorescence intensity (MFI) between CLL cells and T‐cell controls was less than 0.5. Of 60 patients, (34 Ven‐O, 26 Ven‐R), 6 demonstrated pre‐therapy CD20 negativity (1 treatment‐naïve, 5 pre‐treated) and 10/29 (34%) with measurable residual disease (MRD) at EOT demonstrated post‐therapy CD20 loss (4 Ven‐O, 6 Ven‐R). Notch receptor 1 ( NOTCH1 ) variants were identified in 5/10 (50%) patients with CD20‐negative MRD, compared to 3/18 (17%) with CD20‐positive MRD and 6/29 (21%) with undetectable MRD. Five patients had longitudinal assessment, with all demonstrating persistent CD20‐negative disease long after antibody exposure (follow‐up 12–39 months). These results have potential implications for future treatment selection and efficacy.

  • Shortened axi-cel manufacturing drives rapid in vivo expansion and shifts the acute toxicity profile in R/R LBCL

    by Brydon Panozzo, Matthew Rubic, Jian Li, Catelyn Cashion, Nicole L. O’LEary, Sergio Farina, Adrian G. Minson, Kylie Baldwin, Mary Sartor, Teresa Marzulli, et al.

  • Open Access

    Dynamic risk stratification using early CAR ‐T expansion in R/R LBCL treated with axicabtagene ciloleucel

    by Brydon Panozzo, Samuel Robinson, Adrian G. Minson, Jian Li, Kylie Baldwin, Hamish W. Scott, Jane Oliaro, Aaron J. N. Wong, Samantha van der Linde, Nicole L. O'LEary, et al.

    Summary: The clinical utility of routine monitoring of chimeric antigen receptor (CAR) T‐cell expansion post‐infusion remains controversial. We conducted a retrospective analysis of a prospectively collected cohort of 176 patients with relapsed/refractory large B‐cell lymphoma (LBCL) treated with axicabtagene ciloleucel (axi‐cel). CAR T‐cell expansion was measured by flow cytometry at days 7, 14 and 28 following infusion with real‐time reporting to the clinical service in 111 patients. We examined the association between CAR T‐cell expansion, efficacy (progression‐free survival [PFS]), toxicity (cytokine release syndrome [CRS] and immune effector cell‐associated neurotoxicity syndrome [ICANS]) and toxicity management, accounting for baseline risk factors. A multivariable model combining day 7 expansion with pre‐lymphodepletion lactate dehydrogenase (LDH) and bridging response demonstrated that robust day 7 expansion (≥48 cells/μL) was independently associated with improved PFS (hazard ratio [HR], 0.43; 95% confidence interval [CI] 0.22–0.83; p = 0.01). Higher day 7 expansion was associated with increased CRS severity and ICANS incidence. Higher corticosteroid exposure reflected this toxicity burden but was not associated with inferior PFS. Thus, incorporating quantitative CAR‐T enumeration into clinical practice may dynamically refine risk stratification post‐infusion and guide individualised management, such as the frequency of monitoring for progressive disease in the era of effective subsequent therapies.